Register Login
Register to leave comments
  • News bot April 29, 2026, 11:21 a.m.

    📋 ANIKA THERAPEUTICS, INC. (ANIK) - Financial Results

    Filing Date: 2026-04-29

    Accepted: 2026-04-29 07:20:27

    Event Type: Financial Results

    Event Details:

    ANIKA THERAPEUTICS, INC. (ANIK) Reports the reporting period Financial Results ANIKA THERAPEUTICS, INC. (ANIK) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 10615
    • Net Income: 0.27
    • EPS: Not disclosed
    • Cash and equivalents: 41020
      • 9 million, led by continued regional expansion and improved market share.Integrity continued to demonstrate strong momentum, with U.S. sales execution driving a 35% increase in procedures year over year and generating $
      • 8 million in revenue. Growth was driven by sustained surgeon adoption in the U.S., the successful launch of larger Integrity sizes that expand addressable tendon applications, and increasing international penetration.Hyalofast PMA engagement with FDA continues to progress and review timeline remains in line with the previously provided timeline.Cingal bioequivalence study enrollment remains on track in preparation for an FDA NDA submission including necessary CMC work to support HA as a drug.OEM channel year over year growth driven by order timing of non
      • orthopedic and US OA Pain Management products including continued strong Monovisc demandTargeted operational investments improving productivity, discipline, and scalability First Quarter 2026 Continuing Operations Financial Summary Revenue $

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Unaudited Revenue 29.61K 26.17K $3.44K +13.16%
    Operating Expenses Selling General Administrative 17.77K 12.91K $4.87K +37.70%
    Operating Expenses Loss From Operations 5.49K 4.28K $1.20K +28.10%
    Operating Expenses Net Loss 5.06K 4.87K $183.00 +3.76%
    Current Assets Prepaid Expenses Other Current Assets 3.94K 3.40K $535.00 +15.74%
    Current Assets Property Equipment Net 39.72K 40.32K $-602.00 -1.49%
    Current Assets Intangible Assets Net 1.65K 1.65K $0.00 +0.00%
    Current Liabilities Accounts Payable 6.34K 6.04K $298.00 +4.93%
    Current Liabilities Other Long Term Liabilities 726.00 701.00 $25.00 +3.57%
    Cash Flows From Operating Activities Net Loss 5.06K 4.87K $183.00 +3.76%
    Changes In Operating Assets And Liabilities Accounts Payable 745.00 47.00 $698.00 +1485.11%
    Changes In Operating Assets And Liabilities Operating Lease Liabilities 468.00 569.00 $-101.00 -17.75%
    Revenue 29.61K 26.17K $3.44K +13.16%
    Selling, General & Administrative 17.77K 12.91K $4.87K +37.70%
    Loss from Operations 5.49K 4.28K $1.20K +28.10%
    Net Loss 5.06K 4.87K $183.00 +3.76%
    Prepaid Expenses and Other Current Assets 3.94K 3.40K $535.00 +15.74%
    Property and Equipment, Net 39.72K 40.32K $-602.00 -1.49%
    Intangible Assets, Net 1.65K 1.65K $0.00 +0.00%
    Accounts Payable 6.34K 6.04K $298.00 +4.93%
    Interest Income 179.00 224.00 $-45.00 -20.09%
    Operating Lease Liabilities 468.00 569.00 $-101.00 -17.75%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ANIKA THERAPEUTICS, INC.
    • Ticker Symbol: ANIK

Search

News categories